SCHEMBL5146396

SCHEMBL5146396

COC(=O)CC(=O)c1cc2ccc(N(C)C)cc2oc1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 4/20 0.66
MIF P14174 1/20 0.57
MAOB P27338 6/20 0.52
ALDH1A1 P00352 4/20 0.52
HPGD P15428 4/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
KMT2A Q03164 2/20 0.52
ATM Q13315 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
CYP2C19 P33261 2/20 0.52
SLC16A1 P53985 2/20 0.52
KDM4E B2RXH2 2/20 0.52
HSD17B10 Q99714 2/20 0.52
USP2 O75604 1/20 0.52
CYP1A2 P05177 1/20 0.52
ALOX15 P16050 1/20 0.52
MAOA P21397 2/20 0.52
GAA P10253 2/20 0.46
GLA P06280 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8681082 0.88 MEN1 (0.70) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL24176806 0.84 SLC16A3 (0.72) SLC16A3MAOBALDH1A1HPGDMEN1
SCHEMBL2030497 0.81 SLC16A3 (0.81) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL839032 0.80 SLC16A3 (1.00) SLC16A3MAOBALDH1A1HPGDMEN1
SCHEMBL2031972 0.80 SLC16A3 (0.78) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL31669653 0.79 SLC16A3 (0.68) SLC16A3MAOBALDH1A1HPGDMEN1
SCHEMBL28456792 0.79 SLC16A3 (0.76) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL14111521 0.79 SLC16A3 (0.76) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL2911594 0.79 MAOB (0.80) SLC16A3MIFMAOBALDH1A1HPGD
SCHEMBL11225033 0.76 SLC16A3 (0.72) SLC16A3MIFMAOBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1624900-A4 METHODS FOR BINDING AGENTS TO BETA-AMYLOID PLAQUES UNIV CALIFORNIA (US) 2007-05-02 EP disclosed
US-20070053831-A1 Methods for binding agents to b-amyloid plaques THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2007-03-08 US disclosed
EP-1624900-A2 METHODS FOR BINDING AGENTS TO BETA-AMYLOID PLAQUES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-02-15 EP disclosed
WO-2005040337-A2 METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070053831-A1 Methods for binding agents to b-amyloid plaques APBA1, CLTB, FABP7 SLC16A3 2974/4885MIF 2127/4885MAOB 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.